KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Depreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E Adjustments
Ratios

TherapeuticsMD (TXMD) Accumulated Depreciation & Amortization (2016 - 2023)

Historic Accumulated Depreciation & Amortization for TherapeuticsMD (TXMD) over the last 14 years, with Q3 2023 value amounting to $2.5 million.

  • TherapeuticsMD's Accumulated Depreciation & Amortization fell 1645.53% to $2.5 million in Q3 2023 from the same period last year, while for Sep 2023 it was $2.5 million, marking a year-over-year decrease of 1645.53%. This contributed to the annual value of $2.4 million for FY2022, which is 2404.87% up from last year.
  • Latest data reveals that TherapeuticsMD reported Accumulated Depreciation & Amortization of $2.5 million as of Q3 2023, which was down 1645.53% from $2.5 million recorded in Q2 2023.
  • TherapeuticsMD's Accumulated Depreciation & Amortization's 5-year high stood at $3.0 million during Q3 2022, with a 5-year trough of $115059.0 in Q2 2019.
  • Over the past 5 years, TherapeuticsMD's median Accumulated Depreciation & Amortization value was $2.1 million (recorded in 2021), while the average stood at $1.8 million.
  • In the last 5 years, TherapeuticsMD's Accumulated Depreciation & Amortization crashed by 7451.18% in 2019 and then surged by 73412.26% in 2021.
  • Over the past 5 years, TherapeuticsMD's Accumulated Depreciation & Amortization (Quarter) stood at $612786.0 in 2019, then surged by 70.07% to $1.0 million in 2020, then soared by 89.12% to $2.0 million in 2021, then increased by 24.05% to $2.4 million in 2022, then rose by 2.37% to $2.5 million in 2023.
  • Its Accumulated Depreciation & Amortization was $2.5 million in Q3 2023, compared to $2.5 million in Q2 2023 and $2.5 million in Q1 2023.